Dialyzer Production Lines — 60-minute course

60 min · self-paced back to training

0Orientation & objectives

This course gives participants a working understanding of how a hollow-fiber hemodialyzer is manufactured — from membrane and fiber bundle through potting, cutting, port assembly, sterilization, and packaging — and where each step intersects the production controls required under the QMSR (21 CFR Part 820 / ISO 13485:2016 § 7.5). Two real, currently-marketed product families, Family A and Family B, are used throughout to ground the material in specified, currently-marketed devices rather than an abstract device class.

Intended audience. Quality-management and quality-assurance consultants who are expert in ISO 13485, TÜV/notified-body audits, and MDSAP, advising dialyzer manufacturers or component suppliers. The course assumes the regulatory-framework knowledge built in the companion QMSR course and concentrates here on the manufacturing side: what actually happens on the production line, and why specific steps draw specific regulatory attention.

Running examples.

Learning objectives. On completion, a participant will be able to: (1) explain the dialyzer manufacturing sequence from fiber bundle to packaged finished device, and identify the step that structurally separates the blood and dialysate compartments; (2) map specific production steps (potting, cutting, sterilization) to the QMSR controls that govern them; (3) use the Family A and Family B product families to illustrate how flux classification, membrane material, and sterilization choice interact in a real, currently-marketed device.

How the course is structured

ElementDetail
FormatSelf-paced; approximately 60 minutes
Formative questions12 multiple-choice, distributed across sections (feedback, not scored)
Final assessment20 multiple-choice questions; pass mark 80% (16 correct)
CurrencyReflects the wiki sources current as of June 2026
Scope note. This course is production-process-centric. It does not re-teach the QMSR framework itself (covered by the companion 90-minute course) — it assumes that context and applies it to the manufacturing floor.

1The dialyzer: membrane, flux class, and two real products

Learning objective. Describe what determines a dialyzer's flux classification, and identify how the two product families illustrate this with real specifications.

What a dialyzer is, mechanically

A dialyzer is a bundle of thousands of semipermeable hollow fibers, potted into a housing with two compartments (blood and dialysate) kept separate except across the fiber wall. FDA classifies it under 21 CFR Part 876, Subpart F — as a conventional hemodialysis system (§ 876.5820) or a high permeability system (§ 876.5860, Kuf > 8 mL/hr/mmHg), both Class II, 510(k).

Membrane material

Polysulfone (PSf) and polyethersulfone (PES) dominate current commercial dialyzers — high thermal/mechanical stability and good chemical/pH resistance, offset by hydrophobicity that is typically addressed by blending with polyvinylpyrrolidone (PVP). Both Family A (a proprietary polysulfone) and Family B (a different proprietary polysulfone) are PSf-family membranes — proprietary formulations of the same base polymer chemistry, not different chemistries.

Flux classification — the textbook bands

ClassKUF (mL/h/mmHg)β₂-M sieving coefficientAlbumin sieving coefficient
Low flux<100
High flux20–400.7–0.8<0.01
Medium cut-off (MCO)40–600.99<0.01
Protein leaking>400.9–1.00.01–0.03
Super high flux40–601.0<0.2

The two real products against this table

Family B fits the textbook bands closely: its high-flux line reports a β₂-M sieving coefficient of exactly 0.7 (squarely inside the 0.7–0.8 high-flux band); its low-flux line's KUF (11–17 mL/h/mmHg) sits just above the <10 cutoff but is clearly distinct from the 20–40 high-flux band.

Family A does not: its β₂-M sieving coefficient (>0.8) and KUF (99–124 mL/h/mmHg) both exceed the high-flux textbook numbers by a wide margin, yet it is marketed simply as "high flux." The lesson: textbook flux bands are academic/clinical conventions for comparing membranes, not enforced regulatory thresholds. The only regulatory binary cut is FDA's Kuf > 8 mL/hr/mmHg line between § 876.5820 and § 876.5860 — and both Family A and Family B's high-flux line clear that bar easily, while Family B's low-flux line (KUF 11–17) is, perhaps counter-intuitively, also above the FDA's 8 mL/hr/mmHg high-permeability threshold despite being "low flux" by the five-category clinical scheme. This is worth sitting with: FDA's binary regulatory cut and the five-class clinical taxonomy are answering different questions and do not align at the same numeric boundary.

The same platform, two flux classes

Family B's low-flux and high-flux 1.6 m² variants share an identical surface area and blood compartment volume (100 mL), the same membrane material and the same sterilization (oxygen-free gamma) — yet their KUF differs roughly 6-fold (14 vs. 85 mL/h/mmHg). The difference is engineered entirely into the membrane's pore-size distribution, not the device's external dimensions. A participant evaluating a dialyzer design change must therefore look inside the membrane specification, not just the device's outer geometry, to know whether a proposed change affects flux class.

Example — design-control implication. A manufacturer changing fiber wall thickness or pore structure to move a product from low-flux to high-flux (or vice versa) is making a design change under ISO 13485 § 7.3.9, almost certainly triggering re-verification of clearance/sieving performance and, very likely, a biocompatibility re-evaluation (different pore structure changes blood-contact surface area and protein interaction).

Check your understanding

1.1 What single change between Family B's low-flux and high-flux 1.6 m² variants accounts for their ~6× difference in KUF?
1.2 Family A's β₂-M sieving coefficient (>0.8) exceeds the textbook "high flux" band (0.7–0.8). What does this illustrate?
1.3 Which FDA threshold separates § 876.5820 (conventional) from § 876.5860 (high permeability) systems?